PMID- 8889680
OWN - NLM
STAT- MEDLINE
DCOM- 19970130
LR  - 20190512
IS  - 0146-4760 (Print)
IS  - 0146-4760 (Linking)
VI  - 20
IP  - 6
DP  - 1996 Oct
TI  - Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in 
      plasma and urine by HPLC-DAD and GC-MS.
PG  - 432-40
AB  - In Europe, the compound 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Adam), 
      in addition to cannabis, is the most abused illicit drug at all-night "techno" 
      parties. Methods for the determination of MDMA and its metabolites, 
      4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-dihydroxy-methamphetamine (HHMA), 
      3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxyamphetamine (HMA), and 
      3,4-dihydroxyamphetamine (HHA), in biological fluids were established. Plasma and 
      urine samples were collected from two patients in a controlled clinical study 
      over periods of 9 and 22 h, respectively. MDMA and MDA were determined in plasma 
      and urine by reversed-phase high-performance liquid chromatography with diode 
      array detection (HPLC-DAD) after solid-phase extraction on cation-exchange 
      columns. Acidic or enzymatic hydrolysis was necessary to detect HMMA, HMA, HHMA, 
      and HHA, which are mainly excreted as glucuronides. Gas chromatography-mass 
      spectrometry (GC-MS) was used for confirmation. Sample extraction and on-disc 
      derivatization with heptafluorobutyric anhydride (HFBA) were performed on 
      Toxi-Lab SPEC solid-phase extraction concentrators. After administration of a 
      single oral dose of 1.5 mg/kg body weight MDMA, peak plasma levels of 331 ng/ml 
      MDMA and 15 ng/mL MDA were measured after 2 h and 6.3 h, respectively. Peak 
      concentrations of 28.1 micrograms/mL MDMA in urine appeared after 21.5 h. Up to 
      2.3 micrograms/mL MDA, 35.1 micrograms/mL HMMA, and 2.1 micrograms/mL HMA were 
      measured within 16-21.5 h. Conjugated HMMA and HHMA are the main urinary 
      metabolites of MDMA.
FAU - Helmlin, H J
AU  - Helmlin HJ
AD  - Institute of Pharmacy, University of Bern, Switzerland.
FAU - Bracher, K
AU  - Bracher K
FAU - Bourquin, D
AU  - Bourquin D
FAU - Vonlanthen, D
AU  - Vonlanthen D
FAU - Brenneisen, R
AU  - Brenneisen R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Anal Toxicol
JT  - Journal of analytical toxicology
JID - 7705085
RN  - 0 (Fluorocarbons)
RN  - 0 (Hallucinogens)
RN  - 0 (Ion Exchange Resins)
RN  - 117652-28-5 (4-hydroxy-3-methoxymethamphetamine)
RN  - 15398-87-5 (alpha-methylepinine)
RN  - 336-59-4 (heptafluorobutyric anhydride)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 555-64-6 (alpha-methyldopamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - R7339QLN1C (Deoxyepinephrine)
SB  - IM
CIN - J Anal Toxicol. 1997 Nov-Dec;21(7):591. PMID: 9399134
MH  - 3,4-Methylenedioxyamphetamine/blood/urine
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Chromatography, High Pressure Liquid
MH  - Deoxyepinephrine/analogs & derivatives/blood/urine
MH  - Female
MH  - Fluorocarbons/chemistry
MH  - Gas Chromatography-Mass Spectrometry
MH  - Hallucinogens/administration & dosage/*blood/urine
MH  - Humans
MH  - Hydrolysis
MH  - Ion Exchange Resins/chemistry
MH  - Male
MH  - Methamphetamine/analogs & derivatives/blood/urine
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*blood/urine
MH  - Reference Standards
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1093/jat/20.6.432 [doi]
PST - ppublish
SO  - J Anal Toxicol. 1996 Oct;20(6):432-40. doi: 10.1093/jat/20.6.432.